Skip to main content
v2026.11,610 entries · CC-BY 4.0
LAC HealthLaboratory & ResearchLab & research supplies.Reagents, consumables, PPE & instruments — documented, fast, chain-of-custody shipping.Shop lac.us lac.us

Editorial · CASRAI · Research integrity and misconduct

Salk Institute’s Satchidananda Panda to Resign Following Sexual Misconduct Investigation

Circadian biologist Satchidananda Panda will leave the Salk Institute for Biological Studies on 13 August 2026, ending a 22-year tenure, after an independent investigation into sexual misconduct allegations. Panda denies the allegations; Salk has not released the investigation’s findings.

Published 6 Aug 2026· 4 minute read

Ask about this story

Answers are drawn from this article and the rest of the CASRAI corpus, with a link to every source.

Answers are AI-generated from CASRAI’s own published pages and can be wrong, so check the linked sources before relying on one; your question is logged without personal data — never sold, never used to train a third-party model — to show us what CASRAI is missing, so please do not type personal or confidential details. How we use this

CASRAI is the reference for research administration — bookmark it for the next question.

Satchidananda Panda, a prominent circadian biology researcher at the Salk Institute for Biological Studies in La Jolla, California, has told the institute he intends to resign, effective 13 August 2026, following an independent investigation into allegations of sexual misconduct. The departure ends a 22-year association with Salk. Panda denies the allegations.

The story was first reported by Science, which reviewed an internal email sent to Salk faculty by institute president Gerald Joyce announcing Panda’s resignation decision.

What the investigation examined

According to Science‘s reporting, the allegations that prompted the investigation came from a research assistant in Panda’s lab, who raised workplace-conduct concerns through official channels earlier in 2026. The specific allegations reported include that Panda gave the assistant massages in his office, became angry when she declined to reciprocate with a foot massage, made sexually explicit remarks, and drank alcohol with her during office meetings — and that she feared refusing his conduct could harm her career prospects.

Salk retained an outside employment-law attorney, Renée Schor, who began interviewing lab members in March 2026; the inquiry stretched over several months. On 1 July 2026, Salk told lab members that the investigation had concluded — but the institute has not released, and has said it will not share, the investigation’s findings. As of this writing, no public report or summary of conclusions has been made available.

Panda’s response

In a statement reported by Science, Panda said: “I deny the allegations and accusations. I am deeply committed to maintaining a safe, respectful, and professional environment.” He has indicated he plans to continue writing, including a book on the health applications of circadian biology.

A prior allegation at the same institute

This is reported to be at least the second time Salk has investigated Panda over harassment-related allegations. A previous inquiry concerned a former lab member who alleged Panda suggested sharing a hotel room with them during a scientific conference; reporting indicates the institute took some form of disciplinary action following that earlier matter, though the specifics of that action have not been publicly detailed.

Who is Satchidananda Panda

Panda is a widely cited researcher in circadian biology, known in particular for research on time-restricted eating (a form of intermittent fasting keyed to the body’s daily rhythms) and on light-sensing pathways that regulate circadian rhythms. He is a co-author of consumer-facing books on circadian health and was elected an AAAS Fellow in 2023. His public profile — well beyond typical academic-research visibility, extending into popular health and wellness media — is part of why his departure from Salk is drawing coverage outside specialist research-integrity outlets.

What is — and isn’t — known

Several elements of this case remain genuinely unresolved and should be read as such rather than treated as settled fact:

  • No findings have been made public. Salk has confirmed an investigation concluded but has declined to disclose what it found. It is not publicly known whether the investigation substantiated, partially substantiated, or did not substantiate the specific allegations reported.
  • Resignation is not an admission. Panda has explicitly denied the allegations. A resignation, on its own, is not evidence of a finding against him, and readers should not conflate the two.
  • The timing is prospective, not retrospective. As of publication, Panda remains affiliated with Salk; his resignation takes effect 13 August 2026, after this piece was drafted. Institutional and public reaction, and any further disclosure, may follow that date.

Why this matters beyond one lab

Cases like this one illustrate a recurring transparency gap in how independent, non-university research institutes handle misconduct findings. Unlike universities, which in the United States are frequently subject to public-records requirements or Title IX disclosure obligations that can eventually surface investigation outcomes, private nonprofit research institutes such as Salk are not generally bound by the same disclosure regimes. That leaves institutions free to confirm that an investigation occurred and concluded, and that a resignation followed, without ever stating what the investigation actually found — a pattern research-integrity observers have long flagged as leaving trainees, the scientific community, and the public with an incomplete picture, even when an outcome (departure) is known.

CASRAI will continue to track developments in this story, including any further disclosure around Panda’s 13 August 2026 departure date, as part of its ongoing coverage of research-integrity and misconduct-investigation practice.

Sources

This is a developing story. CASRAI has not independently verified the underlying allegations and reports here only what has been stated by the parties involved and reported by named sources; the investigation’s findings have not been made public by the Salk Institute.

Related editorial in this domain

More on Research integrity and misconduct

8 Aug 2026

Study Finds the Brain Processes Language Complexity Even Under General Anesthesia

Baylor College of Medicine researchers recorded individual hippocampal neurons in epilepsy-surgery patients under general anesthesia and found the brain still distinguishes nouns, verbs, and adjectives, and even predicts upcoming words — evidence of structured language processing without consciousness. Because the data can only be collected while the patient is unconscious, all consent has to be obtained pre-operatively, a genuinely distinct human-subjects-ethics scenario from research where a participant can object in real time.

8 Aug 2026

Eye-Tracking Study Finds Early Attentional Marker of Depression Risk in Children

A two-year Binghamton University study tracking 242 children’s eye movements toward emotional faces found a measurable attention marker linked to depression risk — one that shifts differently depending on whether a child’s mother has a history of major depressive disorder. Because the study collects family mental-health-history data on minors and assesses inherited depression risk, it required heightened IRB review and parental consent, a genuine human-subjects-ethics angle.

8 Aug 2026

THC Medication Dronabinol Eliminates PTSD Nightmares for a Third of Patients in Industry-Funded Trial

In a Charité-led, double-blind, placebo-controlled trial of 170+ PTSD patients, the THC medication Dronabinol cut nightmare severity nearly twice as much as placebo over ten weeks, and more than a third of treated patients stopped having nightmares entirely. The trial was funded by Bionorica SE, a pharmaceutical manufacturer with a commercial stake in THC-based products — a genuine conflict-of-interest disclosure story — and its at-home, self-administered dosing design in a trauma-exposed population raises real research-ethics protocol questions.

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →